Soft tissue sarcomas are a heterogeneous group of mesenchymal tumors that account for approximately 12 000 new cancer cases and almost 5000 deaths each year in the United States. For large (>5 cm), high-grade sarcomas of the extremity, surgical resection and radiation therapy can achieve local control in approximately 90% of patients.1,2 However, these patients are at risk for developing metastases to the lung. Therefore, in some sarcoma centers, patients with high-risk, localized sarcoma also receive chemotherapy. Even with systemic therapy, many patients die. Therefore, the European Organization for Research and Treatment of Cancer (EORTC) initiated a multinational, multi-institutional phase 3 randomized clinical trial (EORTC 62961-ESHO 95) to evaluate whether adding regional hyperthermia to chemotherapy improves outcomes for patients with localized high-risk soft tissue sarcoma.
Dewhirst MW, Kirsch D. Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma. JAMA Oncol. 2018;4(4):493–494. doi:https://doi.org/10.1001/jamaoncol.2017.4941
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: